The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1409
ISSUE1409
February 4, 2013
Quillivant XR - An Extended-Release Oral Suspension of Methylphenidate
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Quillivant XR - An Extended-Release Oral Suspension of Methylphenidate
February 4, 2013 (Issue: 1409)
The FDA has approved a once-daily, extended-release
oral suspension of methylphenidate (Quillivant XR – Pfizer) for treatment of attention-deficit/hyperactivity
disorder (ADHD). It is the first liquid formulation of the
drug to be marketed for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.